<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490617</url>
  </required_header>
  <id_info>
    <org_study_id>MISO DIU 01</org_study_id>
    <nct_id>NCT03490617</nct_id>
  </id_info>
  <brief_title>Misoprostol Prior to IUD Insertion in Nullipara</brief_title>
  <official_title>Misoprostol Prior To Cupper Intra Uternine Device Insertion In Nullipara: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Materno Infantil Prof. Fernando Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Materno Infantil Prof. Fernando Figueira</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of misoprostol at a dose of 400 µg administered vaginally four hours prior to IUD&#xD;
      insertion increased the ease of insertion and reduced the incidence of pain during the&#xD;
      procedure, although the frequency of cramps increased following misoprostol use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nulligravidas women of reproductive age were submitted to IUD insertion between July 2009 and&#xD;
      November 2011 at the Instituto de Medicina Integral Prof. Fernando Figueira in Recife,&#xD;
      Pernambuco, Brazil. A total of 179 women were randomly allocated to two groups: 86 to use 400&#xD;
      µg of misoprostol vaginally four hours prior to IUD insertion and 93 to use placebo. Risk&#xD;
      ratios (RR) were calculated as measures of relative risk, together with their 95% confidence&#xD;
      intervals (95%CI). The number needed to treat (NNT) and the number needed to harm (NNH) were&#xD;
      also calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical dilatation</measure>
    <time_frame>four hours after misoprostol use</time_frame>
    <description>the frequency of women with cervical dilation ≤ 4 mm (measured by inserting a #4 Hegar dilator through the internal orifice of the cervix uteri immediately prior to IUD insertion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difficulty in inserting IUD</measure>
    <time_frame>four hours after misoprostol use</time_frame>
    <description>subjective difficulty (as reported by the investigator) in inserting the IUD and classified as difficult, very difficult and easy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at insertion</measure>
    <time_frame>four hours after misoprostol use</time_frame>
    <description>judged subjectively by the woman and evaluated by the investigator using a visual analogue scale (VAS). The scale ranged from 0 to 10, in which zero is the absence of pain and 10 the worst pain imaginable.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subjective sensation as reported by the woman</measure>
    <time_frame>four hours after misoprostol use</time_frame>
    <description>the woman's subjective evaluation of the procedure (IUD insertion)was classified as not disagreeable, slightly disagreeable, disagreeable or very disagreeable.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Family Planning</condition>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal misoprostol (400 μg) 4 hours prior to IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vaginal placebo tablets 4 hours prior to IUD insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal misoprostol</intervention_name>
    <description>To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Vaginal Misoprostol Group</arm_group_label>
    <other_name>Prostokos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Nulliparous women&#xD;
&#xD;
          -  No chirurgical procedure in the cervix&#xD;
&#xD;
          -  Wish to use IUD as a contraceptive method&#xD;
&#xD;
        Exclusion criteria are as follows:&#xD;
&#xD;
          -  Presence of active cervical infection visible upon speculum exam (purulent cervicits)&#xD;
&#xD;
          -  Pelvic Inflammatory Disease (PID) or other uterine infection diagnosed within the last&#xD;
             3 months (based on self-report or clinical documentation)&#xD;
&#xD;
          -  Pregnancy ending less than 6 weeks prior to enrollment in study&#xD;
&#xD;
          -  History of prior IUD placement&#xD;
&#xD;
          -  History of uterine cavity abnormality including Mullerian tract anomalies and&#xD;
             leiomyomas distorting uterine cavity shape&#xD;
&#xD;
          -  History of uterine surgery&#xD;
&#xD;
          -  Allergy or intolerance to misoprostol or other prostaglandin&#xD;
&#xD;
          -  Undiagnosed abnormal vaginal bleeding&#xD;
&#xD;
          -  Malignancy of the genital tract&#xD;
&#xD;
          -  Allergy to any component of the IUD or Wilson's disease (for copper- containing IUDs)&#xD;
&#xD;
          -  Pre-procedure use of anesthesia or analgesia (including use of narcotics,&#xD;
             benzodiazepines, or use of anesthetic beyond use at the tenaculum site)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Medicina Integral Professor Fernando Figueira</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Materno Infantil Prof. Fernando Figueira</investigator_affiliation>
    <investigator_full_name>Melania Amorim</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Intrauterine device</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Nulliparous women</keyword>
  <keyword>Contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

